Enzeevu Injection, Solution
Product Images NDC 61314-504

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Enzeevu (NDC 61314-504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Enzeevu 1)

Illustration showing the labeled parts of a syringe used for ENZEEVU injection, solution 2 mg/.05 mL. The diagram identifies the syringe cap, luer lock, 0.05 mL dose mark, rubber stopper, finger grip, and plunger rod components.*

FDA Label Image

Fig-2 (Enzeevu 2)

An instructional illustration showing hands removing a cap or cover from a syringe, depicting a step in the preparation or administration process for an injection.*

FDA Label Image

Fig-3 (Enzeevu 3)

An instructional illustration depicting two hands preparing a syringe for injection. One hand holds the syringe body while the other hand is removing a protective cap from the syringe needle, indicated by an arrow showing the removal direction.*

FDA Label Image

Fig-4 (Enzeevu 4)

An instructional illustration showing two hands holding an intravitreal injection syringe. One hand grips the syringe barrel near the needle, while the other hand points towards the plunger, demonstrating a handling or administration technique relevant to the ENZEEVU (aflibercept) injection solution.*

FDA Label Image

Fig-5 (Enzeevu 5)

An instructional diagram showing a hand holding a syringe for dosing a 0.05 mL volume. A close-up inset highlights the syringe plunger position aligned to the 0.05 mL mark for accurate measurement of the injection volume.*

FDA Label Image

Fig-6 (Enzeevu 6)

An instructional illustration showing hands opening a vial by removing or lifting the cap. One hand holds the vial steady while the other hand lifts the top cover off. The vial appears to be a medicine container consistent with a drug packaging image.*

FDA Label Image

Fig-7 (Enzeevu 7)

An instructional illustration showing hands holding a vial, with one hand removing the cap from the vial. The image likely pertains to the preparation or handling of the injection solution for ENZEEVU (aflibercept) 2 mg/0.05 mL intravitreal injection.*

FDA Label Image

Fig-8 (Enzeevu 8)

An instructional illustration showing a hand holding a syringe with the plunger partially pulled back, and another hand holding a vial or bottle, with an arrow indicating the connection of the syringe to the vial for drawing medication. The image demonstrates preparation of an intravitreal injection solution.*

FDA Label Image

Fig-9 (Enzeevu 9)

An instructional illustration showing a hand holding a vial while another hand draws liquid into a syringe. A magnified inset highlights the vial's label area, emphasizing careful medication preparation. The image relates to the use of ENZEEVU (aflibercept) injection, solution for intravitreal administration.*

FDA Label Image

Fig-10 (Enzeevu 10)

An instructional illustration showing a person's hands preparing a syringe by attaching or removing a needle cap, with an arrow indicating direction for the needle component. The image is likely part of usage instructions for the ENZEEVU (aflibercept) intravitreal injection.*

FDA Label Image

Fig-11 (Enzeevu 11)

An instructional illustration showing two hands holding a syringe labeled ENZEEVU with a needle pointing upward, demonstrating technique likely related to preparation or administration of the intravitreal injection solution.*

FDA Label Image

Fig-12 (Enzeevu 12)

Illustration showing a syringe with a zoomed-in view highlighting the 0.05 mL liquid measurement mark on the syringe barrel, indicating precise dosing for injection.*

FDA Label Image

Figure 13 (Enzeevu 13)

This image shows two line graphs labeled VIEW 1 and VIEW 2 plotting mean change in visual acuity (letters) over weeks, up to 96 weeks. The graphs compare three treatments: Aflibercept 2 mg Q8 weeks (square marker), Aflibercept 2 mg Q4 weeks (triangle marker), and Ranibizumab 0.5 mg Q4 weeks (circle marker). Each graph depicts changes in visual acuity over time for these treatment groups with numerical values indicated at week 52.*

FDA Label Image

Figure-14 (Enzeevu 14)

Two line graphs titled COPERNICUS and GALILEO showing mean change in visual acuity (letters) on the y-axis over 24 weeks on the x-axis. Both graphs compare aflibercept 2 mg administered every 4 weeks with a control group. Aflibercept groups show substantial improvement in visual acuity, reaching approximately +17.3 and +18 letters, respectively, while control groups remain near baseline or slightly negative.*

FDA Label Image

Figure-15 (Enzeevu 15)

A line graph titled 'VIBRANT' showing mean change in visual acuity (letters) over 24 weeks. It compares two groups: one receiving Aflibercept 2 mg every 4 weeks, represented by a line with triangles showing an increase up to about 17 letters, and a control group represented by a line with circles showing a smaller increase up to about 7 letters. The x-axis is labeled 'Weeks' and the y-axis 'Mean Change in Visual Acuity (letters).*

FDA Label Image

Figure 16 (Enzeevu 16)

Line charts depicting mean change in visual acuity in letters over 100 weeks from two clinical trials, VIVID and VISTA. The charts compare aflibercept 2 mg injections administered every 8 weeks and every 4 weeks, alongside a control group. Visual acuity improves over time with aflibercept treatment, with data points marked for each group across multiple weeks.*

FDA Label Image

Figure 17 (Enzeevu 17)

A bar chart comparing the proportion of patients over time at weeks 8, 12, 24, 40, and 52 among three groups: Control (sham), Aflibercept 2Q16, and Aflibercept 2Q8. The vertical axis represents the proportion of patients in percentages. The chart shows increasing patient proportions over time for all groups, with Aflibercept 2Q8 generally having the highest percentages and Control (sham) the lowest across the weeks.*

FDA Label Image

Vial-carton (Enzeevu 18)

Label for ENZEEVU (aflibercept-abzv) Injection 2 mg/0.05 mL, a human prescription drug in intravitreal injection, solution form. The label highlights a single-dose vial with 40 mg/mL concentration, includes usage instructions, and shows the manufacturer as Sandoz Inc. NDC 61314-504-94 is visible.*

FDA Label Image

Pfs-carton (Enzeevu 19)

ENZEEVU (aflibercept-abzv) injection 2 mg/0.05 mL of 40 mg/mL solution for intravitreal use. The label shows a single-dose pre-filled syringe for injection. It includes usage instructions to discard unused portions and lists carton contents including one sterile single-dose pre-filled glass syringe and prescribing information. Labeler: Sandoz Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.